Vcanbio Cell & Gene Engineering Corp Ltd (SHG:600645) — Market Cap & Net Worth
Market Cap & Net Worth: Vcanbio Cell & Gene Engineering Corp Ltd (600645)
Vcanbio Cell & Gene Engineering Corp Ltd (SHG:600645) has a market capitalization of $1.77 Billion (CN¥12.11 Billion) as of May 6, 2026. Listed on the SHG stock exchange, this China-based company holds position #6730 globally and #1551 in its home market, demonstrating a -8.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vcanbio Cell & Gene Engineering Corp Ltd's stock price CN¥25.87 by its total outstanding shares 467948890 (467.95 Million). Analyse Vcanbio Cell & Gene Engineering Corp Ltd (600645) cash conversion ratio to see how efficiently the company converts income to cash.
Vcanbio Cell & Gene Engineering Corp Ltd Market Cap History: 2015 to 2026
Vcanbio Cell & Gene Engineering Corp Ltd's market capitalization history from 2015 to 2026. Data shows change from $4.45 Billion to $1.77 Billion (-6.68% CAGR).
Vcanbio Cell & Gene Engineering Corp Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vcanbio Cell & Gene Engineering Corp Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.83x
Vcanbio Cell & Gene Engineering Corp Ltd's market cap is 0.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.17x
Vcanbio Cell & Gene Engineering Corp Ltd's market cap is 13.17 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.45 Billion | $708.99 Million | $208.35 Million | 6.28x | 21.37x |
| 2016 | $1.84 Billion | $837.90 Million | $37.86 Million | 2.19x | 48.47x |
| 2017 | $1.94 Billion | $1.32 Billion | $10.37 Million | 1.47x | 187.59x |
| 2018 | $1.11 Billion | $1.32 Billion | $59.25 Million | 0.84x | 18.77x |
| 2019 | $1.16 Billion | $1.39 Billion | $49.69 Million | 0.84x | 23.33x |
| 2020 | $1.34 Billion | $1.32 Billion | -$126.86 Million | 1.02x | N/A |
| 2021 | $1.73 Billion | $1.54 Billion | $155.32 Million | 1.13x | 11.13x |
| 2022 | $1.16 Billion | $1.55 Billion | $112.99 Million | 0.75x | 10.31x |
| 2023 | $1.39 Billion | $1.59 Billion | $106.45 Million | 0.87x | 13.04x |
| 2024 | $1.32 Billion | $1.59 Billion | $100.35 Million | 0.83x | 13.17x |
Competitor Companies of 600645 by Market Capitalization
Companies near Vcanbio Cell & Gene Engineering Corp Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Vcanbio Cell & Gene Engineering Corp Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Vcanbio Cell & Gene Engineering Corp Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Vcanbio Cell & Gene Engineering Corp Ltd's market cap moved from $4.45 Billion to $ 1.77 Billion, with a yearly change of -6.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.77 Billion | +2.66% |
| 2025 | CN¥1.73 Billion | +30.57% |
| 2024 | CN¥1.32 Billion | -4.79% |
| 2023 | CN¥1.39 Billion | +19.17% |
| 2022 | CN¥1.16 Billion | -32.61% |
| 2021 | CN¥1.73 Billion | +28.71% |
| 2020 | CN¥1.34 Billion | +15.83% |
| 2019 | CN¥1.16 Billion | +4.25% |
| 2018 | CN¥1.11 Billion | -42.82% |
| 2017 | CN¥1.94 Billion | +5.97% |
| 2016 | CN¥1.84 Billion | -58.78% |
| 2015 | CN¥4.45 Billion | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Vcanbio Cell & Gene Engineering Corp Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.77 Billion USD |
| MoneyControl | $1.77 Billion USD |
| MarketWatch | $1.77 Billion USD |
| marketcap.company | $1.77 Billion USD |
| Reuters | $1.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vcanbio Cell & Gene Engineering Corp Ltd
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People's Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells, and dental ste… Read more